pharmaphorum

SEPTEMBER 22, 2022

Read on to find out about unlocking the potential of connected commercialisation solutions, what HCPs want from post-pandemic communication, achieving launch excellence in oncology and much more. Achieving launch excellence in oncology. A successful launch in the oncology space is not guaranteed; it is strategically planned and earned.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

DECEMBER 2, 2022

Read on for key stories from this year’s Frontiers Health conference in Italy, unlocking the promise of patient support programmes in oncology, supercharging communications with modular content, and much more. Unlocking the promise of patient support programmes in oncology. A history of medical imaging. Company profile: Vinehealth.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

JULY 12, 2022

GlobalData views the ALL pipeline as unsustainable given the rarity of the disease and, unfortunately, most of the pipeline CAR-T cell products for ALL will never reach the market due to strategic decisions, potentially prioritizing other cancers. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

FDA 52

FDA 52

Pharmaceutical Technology

APRIL 13, 2023

Following the increased use of telemedicine during the Covid-19 pandemic, the potential of digital technologies in communication, data collection, and analysis has become increasingly realised by patients, healthcare systems, and clinical trial sponsors.

Documentation 52

Documentation Communication FDA 52

pharmaphorum

MAY 6, 2022

Combination pricing: access to the future of oncology treatment. pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. Rethinking value: why diverse viewpoints matter.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

MARCH 16, 2022

Merck & Co’s two powerhouse oncology drugs – Keytruda and Lynparza – have failed to show efficacy when used in combination for patients with previously treated metastatic castration-resistant prostate cancer (mCRPC).

Chemotherapy 59

Chemotherapy 59

pharmaphorum

SEPTEMBER 17, 2020

In this issue we hear from a variety of KOLs who are leading pharma comms into a new, digital era to get their views on how pharma can best adapt for the post-COVID world. The right people and the right environment for innovative comms.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies 52

PQA

MARCH 30, 2023

Posters will be available for viewing throughout that day. This year’s poster session takes place on day two of the meeting, Thursday, May 11, from 4:45-6:00 p.m., as part of the networking reception. Conference posters are always full of rich information about a study’s purpose, approach and findings.

Specialty Pharmacies 40

Specialty Pharmacies CPhT Hospitals Clinic Management 40

pharmaphorum

FEBRUARY 26, 2021

Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view. Focus on Rare: the invisible burden of rare diseases. Digitalising drug discovery.

Vaccines 59

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 59

pharmaphorum

JUNE 20, 2022

Verdin and Hadjivasiliou say the calls for change are valid, though there are two ways one can view these appeals for modifications to legislation. Regarding oncology, for example, much has changed about the understanding of cancer since the Orphan Drug Act in the US was signed into law 40 years ago.

FDA 52

FDA 52

pharmaphorum

NOVEMBER 2, 2020

It’s time for pharma to take a 360-degree view of its clinical trial data and step into the future with near real-time study management. • Read the latest issue Deep Dive: Digital Health Innovation 2020 in full. Subscribe to future issues of Deep Dive. The post Deep Dive: Digital Health Innovation 2020 appeared first on.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies 59

pharmaphorum

JANUARY 22, 2021

Analysis of prescribing changes. Among HER2+ breast cancer patients in this claims analysis, there was a significant decline of about 41% in terms of the total number of claims using infusion treatment (including Enhertu, Herceptin, Herzuma, Kadcyla, Ogivri, Perjeta, and Trazimera) from oncologists from February to June 2020.

Specialty Pharmacies 105

Specialty Pharmacies Pharmaceutical Companies Pharmaceutical Companies Vaccines 105

pharmaphorum

DECEMBER 14, 2020

pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. . • Read the latest issue Deep Dive: Patients and Partnerships 2020 in full.

Pharmaceutical Companies 76

Pharmaceutical Companies Pharmaceutical Companies FDA 76

pharmaphorum

MAY 21, 2021

Data announced ahead of this year’s American Society of Clinical Oncology (ASCO) conference suggest that Gilead and CAR-T rivals Bristol-Myers Squibb and Novartis better watch their backs as Allogene announced plans for a pivotal study this year.

53

53

European Pharmaceutical Review

DECEMBER 6, 2022

To ensure applicability for the future, these applications were excluded from our analysis. Of the remaining 11, most products submitted for early access were oncology drugs and two products, Adtralza and Rinvoq, for atopic dermatitis 3. Of these, six concerned COVID-19 medications and were submitted in exceptional circumstances.

Chemotherapy 89

Chemotherapy 89

ISPE

NOVEMBER 3, 2022

She noted that many drugs intended for oncology, diabetes, and advanced therapies are assessed centrally in the EMA and trying to harmonize as much as possible, including introducing centralized procedures for generic drugs. method of manufacture and analysis), and accept some variability in other areas?

Communication 98

Communication FDA Documentation Vaccines 98

pharmaphorum

MARCH 8, 2022

Aside from being a fascinating and rewarding career, life sciences also really nurture some of the qualities women naturally possess, such as analysis, multitasking, understanding and listening. My biggest role model was Albert Einstein, as he was, in my view, by far the cleverest person who ever lived.

Hospitals 98

Hospitals Communication 98

pharmaphorum

JANUARY 27, 2023

Physicians and staff have a significant responsibility to maintain the quality of a trial through important procedures, including patient chart analysis, to grasp key insights that will have an impact on patient care decisions. The post Tackling ongoing staffing burnout rates through AI-enabled precision oncology appeared first on.

Medical Records 111

Medical Records Patient Care Hospitals 111

pharmaphorum

OCTOBER 17, 2022

Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed. Dr. Marie-Louise Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development.

Immunization 115

Immunization 115

pharmaphorum

NOVEMBER 17, 2022

Healthcare professionals trust MSLs to keep them informed and up-to-date about the latest treatments, especially in fast-moving areas like oncology. As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important.

Communication 115

Communication Pharmaceutical Companies Pharmaceutical Companies 115

pharmaphorum

SEPTEMBER 8, 2022

It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). The post Are radiopharmaceuticals the next breakthrough in oncology? Once in the body, the targeting molecule can deliver the radioactive molecule to the cancer cells.

Compounding 105

Compounding FDA 105

pharmaphorum

APRIL 26, 2022

Ben Hargreaves speaks to companies that are developing therapies not just in gastrointestinal conditions but also in broader areas, such an immuno-oncology. 4D Pharma, another biotech working in the space, has a pipeline of products that predominantly target either immuno-oncology or central system disorders indications.

Immunization 115

Immunization FDA 115

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment.

Vaccines 134

Vaccines Immunization Compounding Pharmaceutical Companies 134

pharmaphorum

SEPTEMBER 30, 2022

Novel oncologic drugs continue to command premium pricing, driven by a combination of unmet needs, and delivering often-iterative, sometimes-significant improvements in survival or maintenance of a progression-free state. The post Low-Priced Oncology Disruptors: The Cuckoo in the PD-1/PD-L1 Nest or the Runt of the Clutch?

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

pharmaphorum

DECEMBER 22, 2022

From a prevention point of view, she continued, it is important to look at the variation between EU member states. For example, HPV vaccine rates in Malta are 97%; in Bulgaria, they are 2%.

Vaccines 98

Vaccines Communication 98

pharmaphorum

MAY 30, 2022

The American Society of Clinical Oncology, or ASCO, conference is just around the corner, but one subgroup of cancer researchers just had their own gathering, as breast cancer researchers came together in person for the first time since the start of the pandemic at the ESMO Breast Cancer congress. The Trojan horse.

Chemotherapy 116

Chemotherapy Immunization 116

pharmaphorum

DECEMBER 20, 2022

Oncology trial starts reached historic highs in 2021, and a record 30 oncology novel active substances were launched globally the same year, according to research by IQVIA. In recent years, those involved in the research and development of new oncology treatments have delivered ground-breaking therapies.

Immunization 98

Immunization Patient Care Hospitals 98

pharmaphorum

DECEMBER 19, 2022

Nonetheless, resources only explain part of the differences in oncological performance, she said. Rizvi replied that there aren’t large-scale studies or a crisis analysis plan in Europe for oncology. times more likely to be taken up by higher-income people). Crisis and cancer control. Fitzgerald opened the discussion.

Documentation 97

Documentation Hospitals Communication Vaccines 97

pharmaphorum

FEBRUARY 4, 2022

Decision makers in the healthcare industry including payers, especially those who rely on the use of cost-effectiveness analysis (CEA) to evaluate new drugs, are often criticised for failing to capture the holistic value of drugs in their health technology assessments (HTAs). Table 1: Data collection methods (Source: CRA analysis).

103

103

pharmaphorum

SEPTEMBER 27, 2022

As new and effective innovations emerge, particularly in an area of acute need, such as oncology, the financial rewards for such treatments are rich. Another advantage that Halioua raised is one that many are looking at: the synergy between cancer vaccines and current checkpoint inhibitor treatments. billion.

Vaccines 97

Vaccines Immunization 97

pharmaphorum

OCTOBER 27, 2022

Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas and GISTs) at the Centre Léon Bérard (CLB), a hospital 100% dedicated to cancer care and research. Ovarian cancer in Europe, the UK, and beyond.

Chemotherapy 94

Chemotherapy Hospitals FDA 94

pharmaphorum

JANUARY 19, 2023

This could be a major step forward for immuno-oncology therapy, or, as Chopra puts it, “another pillar in our armamentarium against cancer”. View the video below and stay tuned for more live chats from JP Morgan Week. Chopra also talks a little bit about plans so far for the future of Aethon.

97

97

pharmaphorum

JULY 6, 2022

A new cross-sectional study has found that the FDA green lit 95% of the 89 new oncology therapies approved between 2010 and 2019 before the EMA, with the Europeans trailing the Americans by a median of 241 days. The past decade has seen huge advances in cancer therapy, with a swathe of first-in-class or breakthrough therapies being developed.

FDA 98

FDA 98

pharmaphorum

FEBRUARY 4, 2021

For World Cancer Day, David Long, business unit director of Oncology at MSD UK tells pharmaphorum about the company’s ‘Do It Yourself’ campaign launched in the North East to raise awareness of lung cancer symptoms.

Chemotherapy 133

Chemotherapy Compounding 133

pharmaphorum

NOVEMBER 9, 2021

Once widely acknowledged as so special that only scientists and clinical specialists need to apply, oncology has become exponentially more clinically targeted and sophisticated over the last decade. The success of branding in immuno-oncology. Michael Gaschler, PhD , Senior Consultant, Oncology, Cerner Enviza.

Cerner 98

Cerner 98

pharmaphorum

OCTOBER 22, 2020

Cancer doesn’t end when treatment stops – it’s a lifelong journey and people need support throughout, says patient advocate Megan-Claire Chase. No one gets through cancer unscathed. People are usually left with a mixture of treatment aftereffects, toxic positivity, and lingering anger to deal with.

Chemotherapy 137

Chemotherapy 137

pharmaphorum

JANUARY 7, 2022

Having worked in the pharmaceutical industry for more than 20 years, I have witnessed great strides and major progress in oncology research and development and related clinical practice. In addition, in oncology, the collection of patient-reported outcomes (PROs) in clinical trials have been found to be strong predictors of overall survival.

Patient Care 105

Patient Care 105